Back to Condition
Fucosidosis
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Condition

Fucosidosis

Fucosidosis is a rare, progressive lysosomal storage disorder that affects multiple body systems, particularly the brain, leading to a decline in cognitive and physical skills.

Overview

Fucosidosis is a condition that affects many areas of the body. Affected individuals experience intellectual disabilities that worsen with age, often losing previously learned skills such as walking or talking. The condition is considered a spectrum of severity rather than distinct types.

Symptoms

Signs and symptoms may include:

  • Slow growth and abnormal bone development (dysostosis multiplex)
  • Rigid or stiff muscles (spasticity)
  • Clusters of enlarged blood vessels on the skin (angiokeratomas)
  • Distinctive "coarse" facial features
  • Frequent respiratory infections
  • Enlarged liver and spleen (hepatosplenomegaly)
  • Seizures

Causes & Risk Factors

Fucosidosis is caused by variants in the FUCA1 gene, which provides instructions for making the enzyme alpha-L-fucosidase. This enzyme is responsible for breaking down sugar molecules (oligosaccharides) attached to fats and proteins. When this enzyme activity is reduced or eliminated, these compounds accumulate within cells, particularly in the brain, liver, spleen, and skin.

Because the buildup occurs within lysosomes (the cell's recycling compartments), fucosidosis is classified as a lysosomal storage disorder.

Inheritance

Fucosidosis is inherited in an autosomal recessive pattern. This means both copies of the FUCA1 gene in each cell must have a variant to cause the disorder. Parents of an affected individual each carry one copy of the altered gene but typically do not exhibit symptoms of the condition.

Frequently Asked Questions

Diagnosis usually starts with a detailed medical history and physical exam, followed by a blood test measuring alpha‑L‑fucosidase enzyme activity. If the enzyme level is low, a genetic test for mutations in the FUCA1 gene confirms the diagnosis. Imaging studies such as X‑rays can show dysostosis multiplex, and MRI may reveal brain changes.
Currently there is no cure, but enzyme replacement therapy (ERT) is being studied in clinical trials and may help reduce substrate buildup. Hematopoietic stem cell transplantation (HSCT) has been used in some severe cases, potentially slowing neurological decline. Supportive care, including physical therapy and seizure management, is essential.
Physical and occupational therapy can improve mobility and reduce spasticity. Muscle relaxants or antispasticity medications (e.g., baclofen) may be prescribed. Seizure control typically involves antiepileptic drugs such as valproate or levetiracetam, tailored to the individual’s seizure type and response.
Prognosis varies with severity; mild cases may live into adulthood with manageable symptoms, while severe forms often lead to early mortality in childhood or adolescence. Early diagnosis and aggressive supportive care can improve quality of life and potentially extend survival.===
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

Meyahealth

Ⓒ 2026. All rights reserved by MEYA